SCHEMBL7183928

SCHEMBL7183928

CC(C)P(=O)(C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.39
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
CTSS P25774 2/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.35
KCNK3 O14649 1/20 0.35
KCNK9 Q9NPC2 1/20 0.35
CTSK P43235 1/20 0.35
EPHX2 P34913 2/20 0.35
PPARG P37231 1/20 0.35
TYK2 P29597 1/20 0.35
POLQ O75417 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189501 0.86 POLB (0.39) ACP3LMNAGAACTSSALDH1A1
SCHEMBL7175792 0.80 KCNK3 (0.40) ACP3LMNAGAANPSR1TAS2R14
SCHEMBL7180544 0.79 POLQ (0.37) ACP3LMNAGAAAKR1C3AKR1C2
SCHEMBL7190113 0.78 L3MBTL1 (0.40) ACP3ALDH1A1
SCHEMBL7181680 0.78 NPSR1 (0.40) ACP3LMNAGAANPSR1TAS2R14
SCHEMBL7188567 0.77 ALDH1A1 (0.40) ACP3GAAALDH1A1
SCHEMBL7177862 0.77 ALDH1A1 (0.48) ACP3AKR1C3AKR1C2ALDH1A1KCNK3
SCHEMBL7187317 0.77 GAA (0.41) ACP3LMNAGAANPSR1TAS2R14
SCHEMBL7181415 0.75 TAS2R14 (0.41) ACP3LMNAGAACTSSNPSR1
SCHEMBL7175290 0.75 ALDH1A1 (0.39) ACP3LMNAGAANPSR1TAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ACP3 4259/4885LMNA 3241/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ACP3 3961/4885LMNA 3247/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.